CeriBell (CBLL) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its next-generation Clarity algorithm to detect electrographic seizures in newborns pre-term and older. This clearance makes the Ceribell System the first and only AI-powered point-of-care electroencephalograph technology available to detect electrographic seizures in all ages of patients, from pre-term neonates through adults.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Optimistic Buy Rating for Ceribell, Inc. Driven by Strong Revenue Growth and Strategic Initiatives
- Ceribell, Inc. Poised for Growth: Buy Rating Affirmed Amid Market Expansion and Strategic Initiatives
- Ceribell, Inc. Reports Strong Q3 Growth Amid Challenges
- Ceribell price target lowered to $20 from $36 at TD Cowen
- Ceribell price target lowered to $17 from $21 at JPMorgan